All In Biotech

Drug Trial Radar · NCT06757894

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Efficacy and Safety of Zuberitamab and Bendamustine Combination Treatment Followed by Monotherapy Maintenance in Treatment-naïve Follicular Lymphoma: an Open-label, Prospective, Multicenter, Single-arm Phase II Clinical Study

Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Feb 1, 2028

Study completion Feb 1, 2034

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gansu Cancer Hospital; Ganzhou Cancer Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital of Guangzhou Medical University
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • ZuberitamabDrug

    375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)

  • BendamustineDrug

    90 mg/m², administered on D1-2 of C1-C6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response (CR)Time frame: Up to 6 cycles (each cycle is 28 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.